Targeting MET transcription as a therapeutic strategy in multiple myeloma

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 4, 2009, Pages 587-597

  Phillip, Cornel J ^a,b   Stellrecht, Christine M ^a   Nimmanapalli, Ramadevi ^c   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c TUSKEGEE UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell survival; Flavopiridol; MET; Multiple myeloma; Transcription

Indexed keywords

FLAVOPIRIDOL; MESSENGER RNA; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; RNA SYNTHESIS; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; PHOSPHORYLATION; PIPERIDINES; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RNA POLYMERASE II; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 58849145656     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0770-2     Document Type: Article

References (49)

1. NF Andersen T Standal JL Nielsen L Heickendorff M Borset FB Sorensen N Abildgaard 2005 Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogensis and survival Br J Haematol 2 210 217
2. MV Blagosklonny 2004 Flavopiridol, an inhibitor of transcription: implications, problems and solutions Cell Cycle 3 1537 1542
3. K Bommert RC Bargou T Stuhmer 2006 Signalling and survival pathways in multiple myeloma Eur J Cancer 42 1574 1580
4. JC Byrd BL Peterson J Gabrilove OM Odenike MR Grever K Rai RA Larson 2005 Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from cancer and leukemia group B study 19805 Clin Cancer Res 11 4176 4181
5. JC Byrd TS Lin JT Dalton D Wu MA Phelps B Fischer M Moran KA Blum B Rovin M Brooker-McEldowney S Broering LJ Schaaf AJ Johnson DM Lucas NA Heerema G Lozanski DC Young JR Suarez AD Colevas MR Grever 2007 Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia Blood 109 399 404
6. BA Carlson MM Dubay EA Sausville L Brizuela PJ Worland 1996 Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells Cancer Res 56 2973 2978
7. SH Chao DH Price 2001 Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo J Biol Chem 276 31793 31799
8. SH Chao K Fujinaga JE Marion R Taube EA Sausville AM Senderowicz BM Peterlin DH Price 2000 Flavopiridol inhibits P-TEFb and blocks HIV-1 replication J Biol Chem 275 28345 28348
9. R Chen MJ Keating V Gandhi W Plunkett 2005 Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death Blood 106 2513 2519
10. ZM Chrzanowska-Lightowlers T Preiss RN Lightowlers 1994 Inhibition of mitochondrial protein synthesis promotes increased stability of nuclear-encoded respiratory gene transcripts J Biol Chem 269 27322 27328
11. Y Dai TE Hamm P Dent S Grant 2006 Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry Cell Cycle 5 437 446
12. Dalton WS, Bergsagel PL, Kuehl WM, Anderson KC, Harousseau JL (2001) Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 1:157-177
13. PW Derksen RM Keehnen LM Evers MH van Oers M Spaargaren ST Pals 2002 Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma Blood 99 1405 1410
14. PW Derksen DJ De Gorter HP Meijer RJ Bende M Van Dijk HM Lokhorst AC Bloem M Spaargaren ST Pals 2003 The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma Leukemia 17 764 774
15. A Dispenzieri MA Gertz MQ Lacy SM Geyer TR Fitch RG Fenton R Fonseca CR Isham SC Ziesmer C Erlichman KC Bible 2006 Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points Haematologica 91 390 393
16. W Du Y Hattori T Yamada K Matsumoto T Nakamura M Sagawa T Otsuki T Niikura T Nukiwa Y Ikeda 2007 NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor Blood 109 3042 3049
17. IW Flinn JC Byrd N Bartlett T Kipps J Gribben D Thomas RA Larson K Rai R Petric J Ramon-Suerez J Gabrilove MR Grever 2005 Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity Leuk Res 29 1253 1257
18. S Giordano MF Di Renzo RP Narsimhan CS Cooper C Rosa PM Comoglio 1989 Biosynthesis of the protein encoded by the c-met proto-oncogene Oncogene 4 1383 1388
19. I Gojo B Zhang RG Fenton 2002 The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1 Clin Cancer Res 8 3527 3538
20. M Hallek PL Bergsagel KC Anderson 1998 Multiple myeloma: increasing evidence for a multistep transformation process Blood 91 3 21
21. H Hov RU Holt TB Ro U-M Fagerli H Hjorth-Hansen V Baykov JG Christensen A Waage A Sundan M Borset 2004 A selective c-Met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells Clin Cancer Res 10 6686 6694
22. C Jakob J Sterz I Zavrski U Heider L Kleeberg C Fleissner M Kaiser O Sezer 2006 Angiogenesis in multiple myeloma Eur J Cancer 42 1581 1590
23. J Jurado MJ Prieto-Alamo J Madrid-Risquez C Pueyo 2003 Absolute gene expression patterns of thioredoxin and glutaredoxin redox systems in mouse J Biol Chem 278 45546 45554
24. NL Krett JL Zell RG Halgren S Pillay AE Traynor ST Rosen 1997 Cyclic adenosine-3′, 5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma Clin Cancer Res 3 1781 1787
25. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE, Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM (2001) Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2: RESEARCH0041
26. D Mahadevan L Cooke C Riley R Swart B Simons K Della Croce L Wisner M Iorio K Shakalya H Garewal R Nagle D Bearss 2007 A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors Oncogene 26 3909 3919
27. Maulik G SA T Kijima PC Ma PT Morrison R Salgia 2002 Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition Cytokine Growth Factor Rev 13 41 59
28. CS Mitsiades NS Mitsiades NC Munshi PG Richardson KC Anderson 2006 The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions Eur J Cancer 42 1564 1573
29. A Moghul L Lin A Beedle A Kanbour-Shakir MC DeFrances Y Liu R Zarnegar 1994 Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript Oncogene 9 2045 2052
30. X-Y Pei Y Dai S Grant 2004 The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism Mol Cancer Ther 3 1513 1524
31. BM Peterlin DH Price 2006 Controlling the elongation phase of transcription with P-TEFb Mol Cell 23 297 305
32. FA Piazza C Gurrieri L Trentin G Semenzato 2007 Towards a new age in the treatment of multiple myeloma Ann Hematol 86 159 172
33. D Ribatti B Nico A Vacca 2006 Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma Oncogene 25 4257 4266
34. GD Roodman 2006 New potential targets for treating myeloma bone disease Clin Cancer Res 12 6270s 6273s
35. RR Rosato Y Dai JA Almenara SC Maggio S Grant 2004 Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation Leukemia 18 1780 1788
36. HH Sedlacek 2001 Mechanisms of action of flavopiridol Crit Rev Oncol Hematol 38 139 170
37. C Seidel M Borset H Hjorth-Hansen A Sundan A Waage 1998 Role of hepatocyte growth factor and its receptor c-met in multiple myeloma Med Oncol 15 145 153
38. C Seidel M Borset I Turesson N Abildgaard A Sundan A Waage 1998 Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma study group Blood 91 806 812
39. C Seidel S Lenhoff S Brabrand G Anderson T Standal J Lanng-Nielsen I Turesson M Borset A Waage 2002 Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy Br J Haematol 119 672 676
40. I Semenov C Akyuz V Roginskaya D Chauhan SJ Corey 2002 Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol Leuk Res 26 271 280
41. GI Shapiro 2004 Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol Clin Cancer Res 10 4270s 4275s
42. N Shinomiya CF Gao Q Xie M Gustafson DJ Waters YW Zhang GF Vande Woude 2004 RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival Cancer Res 64 7962 7970
43. RJ Sims III R Belotserkovskaya D Reinberg 2004 Elongation by RNA polymerase II: the short and long of it Genes Dev 18 2437 2468
44. CM Stellrecht N Krett S Rosen V Gandhi 2004 Effect of 8-chloro-adenosine on MET expression and downstream activities in multiple myeloma Proc Am Assoc Cancer Res 45 476 477
45. CM Stellrecht CJ Phillip F Cervantes-Gomez V Gandhi 2007 Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase Cancer Res 67 9913 9920
46. EPM Tjin RWJ Groen I Vogelzang PWB Derksen MD Klok HP Meijer S van Eeden ST Pals M Spaargaren 2006 Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma Blood 107 760 768
47. I Turesson N Abildgaard T Ahlgren I Dahl E Holmberg M Hjorth JL Nielsen A Oden C Seidel A Waage J Westin F Wisloff 1999 Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors Br J Haematol 106 1005 1012
48. GFVW Yu-Wen Zhang 2003 HGF/SF-met signaling in the control of branching morphogenesis and invasion J Cell Biochem 88 408 417
49. B Zhang I Gojo RG Fenton 2002 Myeloid cell factor-1 is a critical survival factor for multiple myeloma Blood 99 1885 1893